ARAC reaffirms need for low-dose oral alpha interferon study. (National Institute of Allergy and Infectious Diseases AIDS Research Advisory Committee)

On February 23, 1995, the NIAID AIDS Research Advisory Committee (ARAC) reaffirmed the need for the institute to conduct a multicenter study to examine the effects of low dose oral alpha interferon (LDOAI) therapy on the symptoms caused by HIV disease.

The ARAC recommended that NIAID identify a different clinical trials mechanism in which to conduct study, giving consideration to the Division of AIDS Treatment Research Initiative (DATRI).

LDOAI products are used in the United States, particularly in communities of people of color. Some practitioners in these communities recommend LDOAI based on reports of its beneficial effect on symptoms associated with HIV …